Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2016 / Article
Special Issue

Gasotransmitters in Biology and Medicine: Molecular Mechanisms and Drug Targets

View this Special Issue

Review Article | Open Access

Volume 2016 |Article ID 9049782 | https://doi.org/10.1155/2016/9049782

Sandesh Panthi, Hyung-Joo Chung, Junyang Jung, Na Young Jeong, "Physiological Importance of Hydrogen Sulfide: Emerging Potent Neuroprotector and Neuromodulator", Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 9049782, 11 pages, 2016. https://doi.org/10.1155/2016/9049782

Physiological Importance of Hydrogen Sulfide: Emerging Potent Neuroprotector and Neuromodulator

Academic Editor: Yanxi Pei
Received06 Apr 2016
Accepted24 May 2016
Published20 Jun 2016


Hydrogen sulfide (H2S) is an emerging neuromodulator that is considered to be a gasotransmitter similar to nitrogen oxide (NO) and carbon monoxide (CO). H2S exerts universal cytoprotective effects and acts as a defense mechanism in organisms ranging from bacteria to mammals. It is produced by the enzymes cystathionine β-synthase (CBS), cystathionine ϒ-lyase (CSE), 3-mercaptopyruvate sulfurtransferase (MST), and D-amino acid oxidase (DAO), which are also involved in tissue-specific biochemical pathways for H2S production in the human body. H2S exerts a wide range of pathological and physiological functions in the human body, from endocrine system and cellular longevity to hepatic protection and kidney function. Previous studies have shown that H2S plays important roles in peripheral nerve regeneration and degeneration and has significant value during Schwann cell dedifferentiation and proliferation but it is also associated with axonal degradation and the remyelination of Schwann cells. To date, physiological and toxic levels of H2S in the human body remain unclear and most of the mechanisms of action underlying the effects of H2S have yet to be fully elucidated. The primary purpose of this review was to provide an overview of the role of H2S in the human body and to describe its beneficial effects.

1. Introduction

Hydrogen sulfide (H2S) is a poisonous gas that is a toxicant in most organs in the human body. It acts as a gaseous signaling molecule and chemical reagent involved in many physiological processes, including the pathogeneses of various diseases such as neurodegenerative disease, heart failure, and diabetes [1, 2]. As a result, the beneficial roles of this compound were neglected for many years due to its toxic nature. However, in recent years, the benefits of gasotransmitters such as nitric oxide (NO) and carbon monoxide (CO) have acted as a fillip to investigating the benefits of H2S [3]. Furthermore, a reevaluation of the endogenous levels of H2S confirmed its existence and advantages in mammalian tissues [4].

H2S is a sulfur analog of water and, due to its weak intermolecular force, exists in a gaseous form that is colorless but has an offensive odor [5]. At a pH of 7.4 in the mammalian body, one-fifth of the total H2S subsists in an undissociated form, with the remaining content existing as hydrosulfide anions (HS) and sulfide (S2−). The high lipid solubility of H2S allows it to easily penetrate the plasma membrane of cells in its undissociated form [6] but it remains unclear whether this undissociated form is physiologically pertinent [7]. Various studies performed on rat, human, and bovine brain tissues have determined that H2S is present at levels of up to 50–160 μmol/L in tissues and that sodium hydrogen sulfide (NaHS) is one of the physiological donors of H2S [8].

Although it is known that H2S protects nerves from oxidative stress, saves photoreceptor cells in the retina from light-induced degeneration, regulates endoplasmic reticulum stress, and defends the kidneys from ischemic reperfusion injury [9], the role of H2S in the central nervous system (CNS) has attracted a lot of attention over the past few decades. The neuromodulation and neuroprotection of nerve cells are a common feature of H2S [9] and its enzymes exert effects in a variety of diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Down’s syndrome, cerebral ischemia, and Huntington’s disease [10, 11]. Additionally, following injury in the peripheral nervous system (PNS), peripheral nerves undergo Wallerian degeneration and macrophages are recruited into the distal nerve pump [12]. The regeneration of these injured peripheral nerves is associated with the demyelination, dedifferentiation, and proliferation of Schwann cells, which takes place serially. Recently, the possible involvement of H2S in demyelinating disorders and nerve degenerative disorders has also been suggested [13, 14].

Thus, the present review focuses on the physiological roles of H2S in different systems and organs, including the CNS, and in peripheral nerve degeneration and regeneration. A consensus regarding findings in these areas will aid in the determination of appropriate avenues for H2S in research investigating neural regeneration and the treatment of neurodegenerative diseases and may lead to potential therapeutic strategies that employ H2S.

2. Biosynthesis of H2S

Two pyridoxal-5′-phosphate- (PLP-) dependent enzymes present in mammalian tissues, cystathionine β-synthase (CBS; EC and cystathionine ϒ-lyase (CSE; EC, are primarily responsible for the biosynthesis of H2S from L-cysteine (L-Cys) [15, 16]. H2S can be produced by other pathways as well. Cysteine first reacts with ketoacids to form 3-mercaptopyruvate via the catalytic action of cysteine aminotransferase (CAT; EC and then 3-mercaptopyruvate is desulfurated by 3-mercaptopyruvate sulfurtransferase (MST; EC to form H2S [17]. H2S is mostly synthesized by cystathionase in the liver, kidneys, enterocytes, and vascular smooth muscle cells, by CBS in the brain, and by MST in cardiac tissues [18]. Recently, it was reported that dihydrolipoic acid (DHLA) and thioredoxin are the endogenous reducing substances that cause MST to release H2S [16] and that CBS is the catalytic agent responsible for the condensations of cysteine and homocysteine, which produces H2S and cystathionine via a β-replacement reaction [19, 20]. The distributions of CBS and CSE in mammalian tissue are different. A cardiovascular study determined that CSE plays a major role in producing H2S under normal physiological conditions [21] while another study found that the MST pathway mainly contributes to its production in the brain and that this pathway is regulated by intracellular calcium (Ca2+) in a concentration-dependent manner [16, 22, 23].

A recent study used Western blot and immunohistochemistry analyses to investigate DAO expression and methylene blue assays to assess H2S biosynthesis and revealed that H2S is also produced from D-cysteine via the enzyme D-amino acid oxidase (DAO) [24]. The H2S production pathway that uses D-cysteine primarily operates in the cerebellum and kidney and, thus, was termed the DAO/MST pathway [25, 26]. Although DAO is confined to peroxisomes and MST is located in the mitochondria, these factors exchange numerous enzymes and metabolites [16]; these findings provide strong support for calling this pathway the DAO/MST pathway. Interestingly, the production of H2S via DAO is subdued by indole-2-carboxylic acid but this effect was not seen with MST [26]. A nonenzymatic pathway for the production of H2S also exists and involves the reduction of elemental sulfur to H2S by reducing equivalents procured via the oxidation of glucose [27]. Either hyperglycemia or the escalation of oxidative stress conditions can nurture the production of H2S via this nonenzymatic route in mammalian erythrocytes [8]. The endogenous production and metabolism of H2S and its aforementioned biosynthetic and transformation pathways are illustrated in Figure 1.

It is believed that two possible mechanisms can explain the release of H2S. First, after its production, H2S may be liberated by the enzymes involved in its synthesis and, second, H2S may be stored and released in response to physiological needs in mammalian tissue [28]. H2S is released from acid-liable sulfur (sulfur atom in iron-sulfur complex) under acidic conditions, while under alkaline conditions bound sulfane-sulfur comes into play; the favorable pH range for its release under these conditions is approximately 5.4 and 8.4, respectively [29]. The discovery of the DAO/MST pathway suggests that additional H2S biosynthetic pathways may be revealed in the future.

3. Interrelationships with Other Gasotransmitters

Although H2S, NO, and CO have similar molecular targets and cellular actions, these compounds also have a tendency to compete with each other. For example, the gasotransmitters CO and NO have particular relationships with CBS [8]. After the initial demonstration of the physiological roles of H2S in 1996 [31], it took 5 more years to determine that NO can bind to CBS and can impede enzymatic activity and that CBS has a high affinity for CO [32]. However, the exact mechanisms underlying these relationships remain unknown. NO also modulates the endogenous production of H2S in smooth muscle cells and vessels [33]. Previously, it was thought that the signaling pathways and functional mechanisms associated with H2S and NO were autonomous, but their combined effects on angiogenesis and vasorelaxation have complicated this issue for researchers. If endothelial NO synthase (eNOS) is blocked, then it fully rescinds the angiogenic effects of H2S whereas the silencing of H2S significantly attenuates the angiogenic effects of NO [34]. Additionally, both H2S and NO activate protein kinase G, as well as its cellular signaling, and 1-H-[1,2,4]oxadiazolo[4-3,-a]quinoxalin-1-one (ODQ), which is a soluble guanylyl cyclase inhibitor that decreases both H2S- and NO-induced angiogenesis [35].

Under severe conditions such as heart inflammation and heart failure events, H2S and NO cooperate and communicate with each other to stimulate thiol-sensitive compounds that produce unambiguous positive outcomes for inotropic and lusitropic heart abnormalities [36]. Ex vivo aortic explants of wild-type and CSE-knockout (CSE-KO) mice were used to explore the possible interaction between H2S and NO and revealed that CSE-KO mice exhibit a significant decrease in vascular neogenesis [37]. The authors also proposed that the interaction of these gasotransmitters stimulates endothelial cell proliferation. The administration of H2S to rats with clinical symptoms of hypoxic pulmonary hypertension has also been shown to increase plasma CO concentrations [38]. CO and H2S act on the same target but have opposite patterns of outcome. For example, coevoked channel activation is completely suppressed by potassium cyanide (KCN; 1 mM) but there are no consequences during H2S-induced channel activation [39]. Thus, the precise nature of the relationship between these gasotransmitters in various physiological pathways remains unclear and requires further investigation. However, even if H2S, NO, and CO compete with each other, their interactions are likely to result in beneficial effects on mammalian physiology.

4. Effect of H2S on the CNS

H2S has a proven neuromodulatory role in the protection of neurons from oxidative stress, as evidenced by its inhibition of hypochlorous acid-mediated oxidative damage [40] and ONOO-mediated protein nitration and cytotoxicity [41] in neuroblastoma cells. Recent studies have also established that H2S plays an important role in the upregulation of the GABA β-receptor at both pre- and postsynaptic sites [42]. Astrocytes and microglial cells play important roles in the regulation of brain pH levels, neurotransmitter levels, and neuronal excitability [43] while microglia are also associated with the progression of neuronal diseases such as AD [44] and PD [45]. H2S evokes Ca2+ waves in astrocytes that trigger a Ca2+ influx via its channels in the plasma membrane [7] and also reversibly increases Ca2+ levels in microglia in a dose-dependent manner [46].

In addition to regulating Ca2+ homeostasis, H2S may also be involved in long-term potentiation (LTP) and the modulation of various neurotransmitters [5]. H2S facilitates hippocampal LTP via the activation of N-methyl-D-aspartate (NMDA) receptors as well as the phosphorylation of these receptors by protein kinase A (PKA) [47] and regulates intracellular Ca2+ level in astrocytes and hippocampal slices [10]. H2S also safeguards neurons by controlling endoplasmic stress via the balancing of membrane potentials and the activation of and cystic fibrosis transmembrane conductance regulator chloride (CFTR Cl) channels [9]. Most neurons in the nucleus solitarius, which are believed to play a role in the cardiovascular system, are depolarized by H2S [48]. Additionally, a donor of H2S, NaHS, is linked to the inhibition of apoptosis, decreases of edema in the brain, and the amelioration of cognitive dysfunction, which could attenuate early brain injury development due to subarachnoid hemorrhage via several mechanisms [49]. The major roles and possible therapeutic targets of H2S are illustrated in Figure 2.

Thus, it can be concluded that H2S exerts protective and modulatory effects on nerve cells, either cooperatively or independently. Although the physical and chemical properties of H2S remain elusive, its roles in these processes have become more clearly defined and most of its mechanisms of action are understood.

4.1. H2S and PD

PD is primarily characterized by cognitive deficiencies resulting from changes in the nucleus basalis of Meynert and the cerebral cortex and the continuous loss of dopaminergic neurons in the mesencephalon [50]. H2S inhibits oxygen consumption and 6-OHDA-evoked nicotinamide adenine dinucleotide phosphate (NADPH) oxidation and activates microglial cells in the midbrain which, in turn, lead to the accumulation of proinflammatory factors in the subcortical part of the forebrain [51]. This is the primary mechanism by which H2S decreases the chances of further neuronal injury and degeneration [52]. The neuroprotective role of H2S has also been demonstrated in experimental rat models of neurotoxin-induced PD [50]. The advantageous effects of H2S are due to its activation or suppression of different protein kinases, such as PKC, PI3K/Akt, p38, JNK, and the ERK-MAPKs [53], which decrease oxidative stress and inflammation and exert antiapoptotic actions.

Although L-Dopa is the most commonly used drug for the treatment of PD due to its ability to maintain dopamine levels, it cannot block or reverse the progression of PD. Additionally, long-term L-Dopa therapy may lead to neurodegeneration [54] and dyskinesia [55] in and of itself. H2S stimulates glutamate transporter functioning and leads to direct sulfa hydration via the ERK/MAPK pathway, which attenuates the production of reactive oxygen species and decreases oxidative stress [56, 57]. Thus, it can be concluded that L-Dopa and H2S may be more effective for the treatment of PD when used in combination. A mouse model of PD constructed using 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) plus probenecid injections results in the destruction of dopaminergic neurons but the administration of H2S increases the survival rate of neurons and is protective against MPTP-induced toxicity [58]. Thus, H2S not only protects peripheral tissues but also effectively treats neurological damage related to PD. Recently, it was shown that drinking coffee and inhaling cigarettes can inhibit monoamine oxidase (MAO) [59], which suggests that there is a lower risk of PD in coffee drinkers and smokers. Cakmak found that coffee contains Prevotella-derived H2S and that H2S is a well-documented constituent of cigarette smoke.

4.2. H2S and AD

AD, which is one of the most familiar types of dementia, is caused by activated microglia and increases in neuritic plaques carrying the β-amyloid protein [60]. This neurodegenerative disease has been exhaustively researched because it affects the cortex and hippocampus and leads to severe cognitive dysfunction [61]. The etiology of AD is multifactorial and presumably includes a number of distinctive etiopathogenic mechanisms [62]. CBS is thought to be the main source of H2S in the brain. In 1996, it was first shown that S-adenosylmethionine, which is a CBS activator, is significantly reduced in subjects with AD [63]. Moreover, the severity of AD is related to altered levels of H2S [64] because the pathological state of AD in the human body has been associated with lower levels of endogenous H2S and the accumulation of homocysteine in the brain [65, 66]. Several series of in vitro and in vivo experiments demonstrated the role of H2S in the promotion of cell growth and preservation of mitochondrial function [67] as well as in the retardation of oxidative stress factors such as amyloid beta peptides (Aβ), malondialdehyde (MDA), hypochlorite (HOCI), and 4-hydroxy-2-nonenal (4-HNE) [68, 69]. In adult male Wistar rats without serious signs of H2S toxicity, spa water with excessive amounts of H2S has the ability to improve cognitive processes by decreasing Aβ deposits and targeting the APP, PST, and ON/4R-tau isoforms [70]. Additionally, NaHS, which is a donor of H2S, retards protein oxidation and lipid peroxidation in the neuroblastoma cells of AD patients [71].

Cerebral atrophy, seizures, and intellectual disabilities can be caused by the autooxidation of homocysteine [72, 73] and hyperhomocysteinemia has been identified in brains of AD patients [74]. H2S protects against and reduces homocysteine-induced toxicity and oxidative stress through its antioxidant properties in the adrenal medulla (PC12 cells) and vascular smooth muscle cells of rats [75, 76]. Synaptic dysfunction and vascular inflammation are also believed to play crucial roles in the pathogenesis of AD [77]. Recent analyses of the expressions of mRNA and synaptic proteins in C57BL/6J wild-type male mice clearly demonstrated that plasma homocysteine-induced alterations in learning and memory processes were associated with synaptic remodeling in the hippocampus [78]. Thus, H2S can influence synaptic remodeling. Vascular dementia (VD) is another common neurodegenerative disorder that, much like AD, is caused by cerebral ischemia. H2S modulates oscillatory coupling in the hippocampus and may represent a possible molecular mechanism underlying the changes in VD patients [79].

Although neurodegenerative pathologies like AD and PD do not initially involve inflammation, various experimental findings suggest that the inflammatory responses of macrophages, microglia, and astrocytes contribute to the progressions of both diseases [14]. The relevance of the CBS, CSE, MST, and CAT enzymes in the development of AD and PD is still unexplained and direct evidence supporting the potential advantages of H2S as a therapeutic strategy for these diseases is unavailable.

4.3. Other CNS Diseases

Various experimental studies have correlated the effects of H2S in different pathological states of the human body. Ischemic stroke increases tissue levels of H2S in the cerebral cortex [80] while H2S has been shown to protect the embryonic brain against ischemia-reperfusion injury [81]. A rat model of febrile seizure is associated with elevated plasma levels of H2S, and Down’s syndrome is known to cause the overaccumulation of H2S in the brain [42]. Similarly, there are increased total plasma homocysteine levels in patients with Huntington’s disease and CBS deficiencies lead to homocystinuria [50]. Additionally, H2S reverses learning and memory problems caused by damage to the hippocampus [82, 83].

5. H2S and the PNS

Even if the most important roles that glial cells play involve the physical and metabolic support of neurons via the maintenance of the extracellular environment, these support cells are often referred to as “glial culprits” because the CNS lacks the ability to regenerate itself, even after injury [84]. On the other hand, Schwann cells in the PNS are best known for their roles in supporting nerve regeneration, conducting nerve impulses along axons, and modulating neuromuscular synaptic activity and nerve development [85]. The possible roles of H2S in peripheral nerve degeneration and regeneration are discussed below and supported with experimental evidence.

5.1. H2S in Peripheral Nerve Degeneration

Based on the degrees of damage in the nerve and surrounding connective tissue, peripheral nerve damage may be classified as neurapraxia, axonotmesis, and neurotmesis, with the latter being a severe type of peripheral nerve injury [86]. As stated above, nerve regeneration after injury is possible in the PNS and involves major events such as Wallerian degeneration, axonal degeneration, remyelination, axonal regeneration, and nerve reinnervation. H2S plays vital roles throughout this process. Axonal regeneration and remyelination begin in the distal pump of injured peripheral nerves and involve axonal degeneration and the degradation of the myelin sheath of Schwann cells, which is termed Wallerian degeneration [87].

The effects of H2S on peripheral nerve degeneration and regeneration may be best explained by recent ex vivo experiments using the sciatic nerves of mice. In these experiments, Park et al. [12] utilized N-ethylmaleimide (NEM), which is an inhibitor of all cysteine peptidases, to inhibit the production of H2S during Wallerian degeneration and found that NEM inhibits not only CSE but also the basal expression of MST. Based on analyses of several markers of Schwann cell dedifferentiation and proliferation, these authors concluded that H2S signaling has great value after peripheral nerve injury regarding myelin fragmentation, axonal degradation, and Schwann cell dedifferentiation and proliferation. Additionally, these findings demonstrated that H2S production influences transcriptional regulation in Schwann cells during Wallerian degeneration. A similar study inhibited these processes via NEM or through several Schwan cell dedifferentiation or immaturity markers including lysosomal associated membrane protein 1 (LAMP1), neurotrophin receptor p75 (), the protein coded by JUN gene (c-jun), and phospho-ERK 1/2 (p-ERK1/2) [15]. Jung and Jeong found that these types of inhibition decreased myelin ovoid fragmentation, axonal degeneration, and Schwann cell dedifferentiation, demyelination, and proliferation through neurotrophin receptors, the MAPK pathway, lysosomal protein degradation, and transcriptional regulation.

The use of these markers in current research has garnered much attention. For example, the LAMP1 marker is related to the degeneration of peripheral nerves, including the nonuniform morphology of myelinated axons, in aged individuals [88]. The function of is associated not only with cell death and survival but also with the maintenance of axonal elongation and the release of neurotransmitters between sympathetic neurons and cardiac myocytes [89]. Furthermore, the reexpression of has been identified in various pathological scenarios, including neurodegenerative disorders [90]. Due to its roles as a protein and a component of a transcription factor, the inactivation of c-jun in mice resulted in delays and/or the failure to properly complete the regeneration procedure and an enhancement of neuronal death [91]. Although the molecular pathways are not yet fully understood, the absence of c-jun causes the complete downregulation of neurotrophic genes such as artemin (Artn), brain-derived neurotrophic factor 1 (BDNF-1), glial cell-derived neurotrophic factor (GDNF), leukemia inhibitory factor (LIF), and nerve growth factor (NGF). These findings suggest that neurotrophins may be a potential target for the treatment of various neuropathies. Studies of the molecular mechanisms involved in those processes explained above have revealed the capability of Schwann cells to regenerate axons and to rescue motor neurons following nerve injury [92].

However, many issues relevant to this process remain unexplained, including the relationships between neurotrophic factors and H2S, H2S production, and remyelination that is associated with the extracellular matrix (ECM) protein, as well as intracellular regulators, hormones, and transcriptional regulators that involve H2S [15]. Other than H2S, the ubiquitin proteasome system (UPS) is another factor that is essential for the regenerative functions of peripheral nerves after injury [93, 94].

5.2. H2S in Peripheral Nerve Regeneration

Other issues associated with the role of H2S in peripheral nerve regeneration involve the responses of Schwann cells in H2S production. Schwann cells are believed to be an important factor in the regeneration process because peripheral axons have no function as H2S producers during Wallerian degeneration [12]. Nerve injury leads to the dedifferentiation of Schwann cells from myelinated cells to immature undeveloped cells [15] and, as discussed in Section 5.1, decreases in H2S production attenuate changes in markers of dedifferentiation. Thus, it is important that reductions in H2S production nurture both the regeneration of axons and the remyelination during the last stage of Wallerian degeneration. Immature undeveloped Schwann cells undergo multiplication and reach the target, injured organ, which is when the possible beneficial effects of H2S come into play. Remyelination is another important process involved in nerve regeneration whereby Schwann cells are able to flourish due to myelination and the inhibition of H2S production (via transcriptional regulation through krox20 and c-jun), which is fundamental to this stage of regeneration [15].

Despite the above findings, very few studies have attempted to analyze the roles that H2S plays in peripheral nerve degeneration and regeneration. Although our research group is currently conducting studies to identify the core effects of H2S, the existing literature strongly supports the importance of H2S in nerve degeneration and regeneration.

6. Other Functions of H2S

The exciting evolution of H2S in the field of neuroscience has revealed its importance not only in the PNS but also in various physiological and pathological conditions. For example, endogenous levels of H2S have been shown to influence exogenous H2S during cell apoptosis [95]. Additionally, the antiproliferative and proapoptotic effects of H2S have a significant influence on various disorders such as vascular graft occlusion, atherosclerosis, and neointimal hyperplasia [96]. H2S also regulates glutathione levels by enhancing the hustle of the cysteine/glutamate antiporter at the cellular level, which directly neutralizes free radicals and reactive oxygen compounds and balances the levels of vitamins C and E in their reduced form [97]. The acute inhalation of H2S protects lungs from injuries induced by ventilators and relaxes pulmonary vascular tissue but epidemiological data suggest that the long-term exposure to even low levels of H2S can cause bronchial hyperresponsiveness [8].

Relative to other parts of the body, the gastrointestinal tract (GIT) contains the largest amount of H2S, where it subsidizes the homeostatic control of GIT mucosal defenses and repairs damage [31]. However, the signaling pathways of H2S in the GIT remain unclear. Other beneficial effects of H2S on translation and transcription include the control of endoplasmic reticulum stress and activating the unfolding protein response. During these processes, CSE increases H2S production and ultimately restores endoplasmic reticulum homeostasis via the sulfa hydration reaction [98]. Additionally, type 1 diabetes is believed to involve the overproduction of H2S [18], and H2S may be helpful for patients with erectile dysfunction due to its involvement in the relaxation of the smooth muscle that causes the erection of the penis [99]. Recently, six fatal cases of H2S poisoning were reported during an attempt to unblock a wastewater cistern in which the primary reason for death was H2S aspiration and because it is a mediator and regulator of various physiological conditions, H2S can have serious toxic effects [100].

The roles of H2S in insulin resistance syndrome and regional ischemic damage, as well as its dose-dependent relationship with methylglyoxal (MG) in vascular smooth muscle cells, also require explanation [3]. Because it is an antioxidant bulwark, H2S has the capacity to sense chromaffin cells and chemoreceptors [101] but it has yet to be determined how H2S increases local blood perfusion and/or ventilation [102]. Further justification is needed for the production of H2S via MST under physiological conditions because this process requires full alkaline conditions [103].

7. Therapeutic Prospect and Potential of H2S

Almost two decades of research on H2S unfastened series of positive outcomes and its potential is expanding every day. Molecular mechanisms of H2S are being uncovered and various types of molecular and sulfa hydration targets are on the phase of identification which may lead us to reveal its biological activities [10]. Several in vivo and in vitro studies on AD and PD model have already proved their therapeutic effectiveness for treatment [40, 68, 104, 105]. Surprisingly, inhaled H2S has found to have protective effect against neuropathic pain and brain edema which has also made researchers think seriously in this topic because we can develop our opinion and research arena on hydrogen sulfide donor compounds against neuropathic pain and brain edema [106, 107]. Even though H2S has to deal with its own double face (toxic and protective) attitude which has pushed it into several controversies, it is recently found that various ion channels in multiple systems and organs advocate the protective role of H2S [108]. Because of the overall effect, H2S-releasing drugs are now under clinical trial after their verified effectiveness in animal model. This trend of clinical trial on finding H2S donors or H2S-releasing drugs can be a very big breakthrough for the treatment of several diseases which are almost incurable till date [109]. H2S-releasing derivatives of mesalamine [110] and diclofenac [111] have already been shown to decrease inflammatory disease and gastric hemorrhagic lesions compared to original drugs and some possibility for the treatment of injured brain after subarachnoid hemorrhage (SAH) via H2S is also a great progress [112] because another study demonstrated that it reduces the level of reactive oxygen species and lipid peroxides malondialdehyde following SAH [113]. Recent studies on the effect of H2S on brain synaptic remodeling and its role in GABA-mediated and glutamate neurotransmission have even increased its prospective potential in physiological standpoint [114]. Even with the difference between community and industry based results, the effect of environmental exposure to H2S on CNS has exposed its novel and diverse role [115]. Neuroprotective role of H2S after traumatic brain injury has also proven its potentiality and efficacy for other CNS related diseases [116]. Thus, it can be summarized that future prospect of H2S in development of new therapeutic strategy is wide and bright.

8. Concluding Remarks

An adequate amount of evidence has been gathered in support of H2S as a gasotransmitter and modulator in mammalian tissue, particularly in the nervous system. H2S is principally produced in the liver, kidney, enterocytes, and vascular smooth muscle cells via cystathionase and partially produced in cardiac tissue by MST. It is catabolized in mitochondria by thiosulfate reductase, and thiosulfate in the urine may be used as a marker of H2S biosynthesis. H2S is capable of both suppressing and promoting inflammation but it remains unclear how these proinflammatory and anti-inflammatory activities can be enhanced or attenuated. The role of H2S in the Schwann cell response to peripheral nerve injury has been well established by experimental evidence, and the importance of H2S signaling during Wallerian degeneration, where it broadly affects Schwann cell dedifferentiation and proliferation, has been repeatedly demonstrated.

The bidirectional relationship between H2S and NO is another area of particular research interest and therapeutic potential. Experimental studies using inhibitors or donors of endogenous H2S have produced clear evidence of its effects but clinical studies that can define its role in the treatment of diseases are necessary. Pharmaceutical companies should accelerate their attempts to formulate, design, and produce H2S-releasing drugs with sustained/controlled release functions as they are likely to be highly innovative for the treatment of neurodegenerative diseases. Thus, therapeutic prospects of H2S signaling for patients with neurodegenerative disease and demyelination disorders are imminent. However, the uncontrollable release, unidentified byproducts, and unclear mechanisms of release and action represent major issues related to the research and clinical use of H2S. Although it is currently a time of great interest and excitement regarding the potential of H2S in medicine and biology, many hypotheses regarding H2S have yet to be supported and many issues remain unanswered. Even though various novel molecular targets have been identified and research is hastily expanding, biomedical research into this gasotransmitter is still in its initial stages.

Competing Interests

The authors reported no potential conflict of interests.

Authors’ Contributions

Sandesh Panthi and Hyung-Joo Chung contributed equally to this work.


This study was supported by Basic Science Research Program through the Korean National Research Foundation (NRF) funded by the Ministry of Science, ICT and Future Planning (Professor Junyang Jung, 2015R1A2A2A01002735; Professor Na Young Jeong, 2015R1C1A1A02036863). The authors would like to thank Sangya Gyawali (University of Pittsburgh, USA) for her valuable help and suggestions.


  1. K. Kashfi and K. R. Olson, “Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras,” Biochemical Pharmacology, vol. 85, no. 5, pp. 689–703, 2013. View at: Publisher Site | Google Scholar
  2. K. M. Holwerda, S. A. Karumanchi, and A. T. Lely, “Hydrogen sulfide: role in vascular physiology and pathology,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 2, pp. 170–176, 2015. View at: Publisher Site | Google Scholar
  3. R. Wang, “Hydrogen sulfide: the third gasotransmitter in biology and medicine,” Antioxidants & Redox Signaling, vol. 12, no. 9, pp. 1061–1064, 2010. View at: Publisher Site | Google Scholar
  4. J. Furne, A. Saeed, and M. D. Levitt, “Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 295, no. 5, pp. R1479–R1485, 2008. View at: Publisher Site | Google Scholar
  5. K. Qu, S. W. Lee, J. S. Bian, C.-M. Low, and P. T.-H. Wong, “Hydrogen sulfide: neurochemistry and neurobiology,” Neurochemistry International, vol. 52, no. 1-2, pp. 155–165, 2008. View at: Publisher Site | Google Scholar
  6. E. Cuevasanta, A. Denicola, B. Alvarez, and M. N. Möller, “Solubility and permeation of hydrogen sulfide in lipid membranes,” PLoS ONE, vol. 7, no. 4, Article ID e34562, 2012. View at: Publisher Site | Google Scholar
  7. H. Kimura, “Production and physiological effects of hydrogen sulfide,” Antioxidants and Redox Signaling, vol. 20, no. 5, pp. 783–793, 2014. View at: Publisher Site | Google Scholar
  8. R. Wang, “Physiological implications of hydrogen sulfide: a whiff exploration that blossomed,” Physiological Reviews, vol. 92, no. 2, pp. 791–896, 2012. View at: Publisher Site | Google Scholar
  9. H. Kimura, “Physiological role of hydrogen sulfide and polysulfide in the central nervous system,” Neurochemistry International, vol. 63, no. 5, pp. 492–497, 2013. View at: Publisher Site | Google Scholar
  10. X. Zhang and J.-S. Bian, “Hydrogen sulfide: a neuromodulator and neuroprotectant in the central nervous system,” ACS Chemical Neuroscience, vol. 5, no. 10, pp. 876–883, 2014. View at: Publisher Site | Google Scholar
  11. S. Gheibi, N. Aboutaleb, M. Khaksari et al., “Hydrogen sulfide protects the brain against ischemic reperfusion injury in a transient model of focal cerebral ischemia,” Journal of Molecular Neuroscience, vol. 54, no. 2, pp. 264–270, 2014. View at: Publisher Site | Google Scholar
  12. B. S. Park, H.-W. Kim, I. J. Rhyu et al., “Hydrogen sulfide is essential for Schwann cell responses to peripheral nerve injury,” Journal of Neurochemistry, vol. 132, no. 2, pp. 230–242, 2015. View at: Publisher Site | Google Scholar
  13. Q.-H. Gong, X.-R. Shi, Z.-Y. Hong, L.-L. Pan, X.-H. Liu, and Y.-Z. Zhu, “A new hope for neurodegeneration: possible role of hydrogen sulfide,” Journal of Alzheimer's Disease, vol. 24, supplement 2, pp. 173–182, 2011. View at: Publisher Site | Google Scholar
  14. P. K. Moore and M. Whiteman, Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, Springer, Berlin, Germany, 2015.
  15. J. Y. Jung and N. Y. Jeong, “Hydrogen sulfide controls peripheral nerve degeneration and regeneration: a novel therapeutic strategy for peripheral demyelinating disorders or nerve degenerative diseases,” Neural Regeneration Research, vol. 9, no. 24, pp. 2119–2121, 2014. View at: Publisher Site | Google Scholar
  16. Y. Mikami, N. Shibuya, Y. Kimura, N. Nagahara, Y. Ogasawara, and H. Kimura, “Thioredoxin and dihydrolipoic acid are required for 3-mercaptopyruvate sulfurtransferase to produce hydrogen sulfide,” Biochemical Journal, vol. 439, no. 3, pp. 479–485, 2011. View at: Publisher Site | Google Scholar
  17. D. Julian, J. L. Statile, S. E. Wohlgemuth, and A. J. Arp, “Enzymatic hydrogen sulfide production in marine invertebrate tissues,” Comparative Biochemistry and Physiology, Part A—Molecular and Integrative Physiology, vol. 133, no. 1, pp. 105–115, 2002. View at: Publisher Site | Google Scholar
  18. P. Kamoun, “H2S, un nouveau neuromodulateur,” Médecine/Sciences, vol. 20, no. 6-7, pp. 697–700, 2004. View at: Publisher Site | Google Scholar
  19. X. Chen, K.-H. Jhee, and W. D. Kruger, “Production of the neuromodulator H2S by cystathionine β-synthase via the condensation of cysteine and homocysteine,” The Journal of Biological Chemistry, vol. 279, no. 50, pp. 52082–52086, 2004. View at: Publisher Site | Google Scholar
  20. O. Kabil, V. Vitvitsky, P. Xie, and R. Banerjee, “The quantitative significance of the transsulfuration enzymes for H2S production in murine tissues,” Antioxidants & Redox Signaling, vol. 15, no. 2, pp. 363–372, 2011. View at: Publisher Site | Google Scholar
  21. L. L. Pan, X. H. Liu, Q. H. Gong, H. B. Yang, and Y. Z. Zhu, “Role of cystathionine γ-Lyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy?” Antioxidants & Redox Signaling, vol. 17, no. 1, pp. 106–118, 2012. View at: Publisher Site | Google Scholar
  22. N. Shibuya, M. Tanaka, M. Yoshida et al., “3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain,” Antioxidants and Redox Signaling, vol. 11, no. 4, pp. 703–714, 2009. View at: Publisher Site | Google Scholar
  23. M. Ishigami, K. Hiraki, K. Umemura, Y. Ogasawara, K. Ishii, and H. Kimura, “A source of hydrogen sulfide and a mechanism of its release in the brain,” Antioxidants and Redox Signaling, vol. 11, no. 2, pp. 205–214, 2009. View at: Publisher Site | Google Scholar
  24. S. Tang, D. Huang, N. An, D. Chen, and D. Zhao, “A novel pathway for the production of H2S by DAO in rat jejunum,” Neurogastroenterology & Motility, vol. 28, no. 5, pp. 687–692, 2016. View at: Publisher Site | Google Scholar
  25. N. Shibuya, S. Koike, M. Tanaka et al., “P33 A novel pathway for the production of hydrogen sulfide from d-cysteine in mammalian cells,” Nitric Oxide, vol. 39, supplement, article S26, 2014. View at: Publisher Site | Google Scholar
  26. N. Shibuya, S. Koike, M. Tanaka et al., “A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells,” Nature Communications, vol. 4, article 1366, 2013. View at: Publisher Site | Google Scholar
  27. G. A. Aboalsamh, “Mitochondria-Targeted Hydrogen Sulphide Donors Protect Renal Cells From Hypoxia Re-Oxygenation Injury,” Electronic Thesis and Dissertation Repository, Paper 2912, 2015. View at: Google Scholar
  28. H. Zhang, P. Wang, G. Chen, H.-Y. Cheung, and H. Sun, “A highly sensitive fluorescent probe for imaging hydrogen sulfide in living cells,” Tetrahedron Letters, vol. 54, no. 36, pp. 4826–4829, 2013. View at: Publisher Site | Google Scholar
  29. H. Kimura, “Hydrogen sulfide: its production, release and functions,” Amino Acids, vol. 41, no. 1, pp. 113–121, 2011. View at: Publisher Site | Google Scholar
  30. M. S. Vandiver and S. H. Snyder, “Hydrogen sulfide: a gasotransmitter of clinical relevance,” Journal of Molecular Medicine, vol. 90, no. 3, pp. 255–263, 2012. View at: Publisher Site | Google Scholar
  31. K. Abe and H. Kimura, “The possible role of hydrogen sulfide as an endogenous neuromodulator,” The Journal of Neuroscience, vol. 16, no. 3, pp. 1066–1071, 1996. View at: Google Scholar
  32. S. Taoka and R. Banerjee, “Characterization of NO binding to human cystathionine β-synthase: possible implications of the effects of CO and NO binding to the human enzyme,” Journal of Inorganic Biochemistry, vol. 87, no. 4, pp. 245–251, 2001. View at: Publisher Site | Google Scholar
  33. W. Zhao, J. Zhang, Y. Lu, and R. Wang, “The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener,” The EMBO Journal, vol. 20, no. 21, pp. 6008–6016, 2001. View at: Publisher Site | Google Scholar
  34. J. Bełtowski and A. Jamroz-Wiśnniewska, “Hydrogen sulfide and endothelium-dependent vasorelaxation,” Molecules, vol. 19, no. 12, pp. 21506–21528, 2014. View at: Publisher Site | Google Scholar
  35. C. Coletta, A. Papapetropoulos, K. Erdelyi et al., “Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 23, pp. 9161–9166, 2012. View at: Publisher Site | Google Scholar
  36. Q.-C. Yong, J. L. Cheong, F. Hua et al., “Regulation of heart function by endogenous gaseous mediators-crosstalk between nitric oxide and hydrogen sulfide,” Antioxidants and Redox Signaling, vol. 14, no. 11, pp. 2081–2091, 2011. View at: Publisher Site | Google Scholar
  37. Z. Altaany, G. Yang, and R. Wang, “Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells,” Journal of Cellular and Molecular Medicine, vol. 17, no. 7, pp. 879–888, 2013. View at: Publisher Site | Google Scholar
  38. D. J. Polhemus and D. J. Lefer, “Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease,” Circulation Research, vol. 114, no. 4, pp. 730–737, 2014. View at: Publisher Site | Google Scholar
  39. V. Telezhkin, S. P. Brazier, S. Cayzac, C. T. Müller, D. Riccardi, and P. J. Kemp, “Hydrogen sulfide inhibits human BKCa channels,” in Arterial Chemoreceptors, pp. 65–72, Springer, New York, NY, USA, 2009. View at: Google Scholar
  40. M. Whiteman, N. S. Cheung, Y.-Z. Zhu et al., “Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain?” Biochemical and Biophysical Research Communications, vol. 326, no. 4, pp. 794–798, 2005. View at: Publisher Site | Google Scholar
  41. M. Whiteman, J. S. Armstrong, S. H. Chu et al., “The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scavenger’?” Journal of Neurochemistry, vol. 90, no. 3, pp. 765–768, 2004. View at: Publisher Site | Google Scholar
  42. Y. Han, J. Qin, X. Chang, Z. Yang, D. Bu, and J. Du, “Modulating effect of hydrogen sulfide on gamma-aminobutyric acid B receptor in recurrent febrile seizures in rats,” Neuroscience Research, vol. 53, no. 2, pp. 216–219, 2005. View at: Publisher Site | Google Scholar
  43. R. C. Koehler, D. Gebremedhin, and D. R. Harder, “Role of astrocytes in cerebrovascular regulation,” Journal of Applied Physiology, vol. 100, no. 1, pp. 307–317, 2006. View at: Publisher Site | Google Scholar
  44. M. Wojtera, B. Sikorska, T. Sobow, and P. P. Liberski, “Microglial cells in neurodegenerative disorders,” Folia Neuropathologica, vol. 43, no. 4, pp. 311–321, 2005. View at: Google Scholar
  45. Y. S. Kim and T. H. Joh, “Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease,” Experimental and Molecular Medicine, vol. 38, no. 4, pp. 333–347, 2006. View at: Publisher Site | Google Scholar
  46. S. W. Lee, Y.-S. Hu, L.-F. Hu et al., “Hydrogen sulphide regulates calcium homeostasis in microglial cells,” Glia, vol. 54, no. 2, pp. 116–124, 2006. View at: Publisher Site | Google Scholar
  47. J.-F. Wang, Y. Li, J.-N. Song, and H.-G. Pang, “Role of hydrogen sulfide in secondary neuronal injury,” Neurochemistry International, vol. 64, no. 1, pp. 37–47, 2014. View at: Publisher Site | Google Scholar
  48. R. Malik and A. V. Ferguson, “Hydrogen sulfide depolarizes neurons in the nucleus of the solitary tract of the rat,” Brain Research, vol. 1633, pp. 1–9, 2016. View at: Publisher Site | Google Scholar
  49. T. Li, H. Liu, H. Xue et al., “Neuroprotective effects of hydrogen sulfide against early brain injury and secondary cognitive deficits following subarachnoid hemorrhage,” Brain Pathology, 2016. View at: Publisher Site | Google Scholar
  50. L.-F. Hu, M. Lu, C. X. Tiong, G. S. Dawe, G. Hu, and J.-S. Bian, “Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models,” Aging Cell, vol. 9, no. 2, pp. 135–146, 2010. View at: Publisher Site | Google Scholar
  51. A. D. Korczyn, “Vascular contribution to dementia in Parkinson's disease,” Neurodegenerative Diseases, vol. 7, no. 1–3, pp. 127–130, 2010. View at: Publisher Site | Google Scholar
  52. L.-F. Hu, M. Lu, P. T. Hon Wong, and J.-S. Bian, “Hydrogen sulfide: neurophysiology and neuropathology,” Antioxidants and Redox Signaling, vol. 15, no. 2, pp. 405–419, 2011. View at: Publisher Site | Google Scholar
  53. C. X. Tiong, M. Lu, and J.-S. Bian, “Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway,” British Journal of Pharmacology, vol. 161, no. 2, pp. 467–480, 2010. View at: Publisher Site | Google Scholar
  54. N. Hattoria, M. Wanga, H. Taka et al., “Toxic effects of dopamine metabolism in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 1, pp. S35–S38, 2009. View at: Publisher Site | Google Scholar
  55. J. Jankovic and M. Stacy, “Medical management of levodopa-associated motor complications in patients with Parkinson's disease,” CNS Drugs, vol. 21, no. 8, pp. 677–692, 2007. View at: Publisher Site | Google Scholar
  56. M. Lu, L.-F. Hu, G. Hu, and J.-S. Bian, “Hydrogen sulfide protects astrocytes against H2O2-induced neural injury via enhancing glutamate uptake,” Free Radical Biology and Medicine, vol. 45, no. 12, pp. 1705–1713, 2008. View at: Publisher Site | Google Scholar
  57. X. Xue and J.-S. Bian, “Neuroprotective effects of hydrogen sulfide in Parkinson's disease animal models: methods and protocols,” Methods in Enzymology, vol. 554, pp. 169–186, 2015. View at: Publisher Site | Google Scholar
  58. M. Wang, J. Zhu, Y. Pan et al., “Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson's disease,” Journal of Neuroscience Research, vol. 93, no. 3, pp. 487–494, 2015. View at: Publisher Site | Google Scholar
  59. Y. O. Cakmak, “Coffee consumption, smoking, and Parkinson's disease? The beneficial role of hydrogen sulfide,” Movement Disorders, vol. 31, no. 3, p. 429, 2016. View at: Publisher Site | Google Scholar
  60. H. Hampel, “Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms,” Journal of Alzheimer's Disease, vol. 33, no. 1, pp. S79–S86, 2013. View at: Publisher Site | Google Scholar
  61. M. S. Parihar and T. Hemnani, “Alzheimer's disease pathogenesis and therapeutic interventions,” Journal of Clinical Neuroscience, vol. 11, no. 5, pp. 456–467, 2004. View at: Publisher Site | Google Scholar
  62. K. Iqbal and I. Grundke-Iqbal, “Opportunities and challenges in developing Alzheimer disease therapeutics,” Acta Neuropathologica, vol. 122, no. 5, pp. 543–549, 2011. View at: Publisher Site | Google Scholar
  63. L. D. Morrison, D. D. Smith, and S. J. Kish, “Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease,” Journal of Neurochemistry, vol. 67, no. 3, pp. 1328–1331, 1996. View at: Google Scholar
  64. X.-Q. Liu, X.-Q. Liu, P. Jiang, H. Huang, and Y. Yan, “Plasma levels of endogenous hydrogen sulfide and homocysteine in patients with Alzheimer's disease and vascular dementia and the significance thereof,” National Medical Journal of China, vol. 88, no. 32, pp. 2246–2249, 2008. View at: Google Scholar
  65. X.-Q. Tang, X.-T. Shen, Y.-E. Huang et al., “Hydrogen sulfide antagonizes homocysteine-induced neurotoxicity in PC12 cells,” Neuroscience Research, vol. 68, no. 3, pp. 241–249, 2010. View at: Publisher Site | Google Scholar
  66. Y. Zhang, Z.-H. Tang, Z. Ren et al., “Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated disease,” Molecular and Cellular Biology, vol. 33, no. 6, pp. 1104–1113, 2013. View at: Publisher Site | Google Scholar
  67. Y.-Y. Liu and J.-S. Bian, “Hydrogen sulfide protects amyloid-β induced cell toxicity in microglia,” Journal of Alzheimer's Disease, vol. 22, no. 4, pp. 1189–1200, 2010. View at: Publisher Site | Google Scholar
  68. S. M. Schreier, M. K. Muellner, H. Steinkellner et al., “Hydrogen sulfide scavenges the cytotoxic lipid oxidation product 4-HNE,” Neurotoxicity Research, vol. 17, no. 3, pp. 249–256, 2010. View at: Publisher Site | Google Scholar
  69. Y.-D. Wen, H. Wang, S.-H. Kho et al., “Hydrogen sulfide protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and oxidative stress,” PLoS ONE, vol. 8, no. 2, article e53147, 2013. View at: Publisher Site | Google Scholar
  70. D. Giuliani, A. Ottani, D. Zaffe et al., “Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms,” Neurobiology of Learning and Memory, vol. 104, pp. 82–91, 2013. View at: Publisher Site | Google Scholar
  71. H.-J. Wei, X. Li, and X.-Q. Tang, “Therapeutic benefits of H2S in Alzheimer's disease,” Journal of Clinical Neuroscience, vol. 21, no. 10, pp. 1665–1669, 2014. View at: Publisher Site | Google Scholar
  72. R. Obeid, A. McCaddon, and W. Herrmann, “The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 12, pp. 1590–1606, 2007. View at: Publisher Site | Google Scholar
  73. M. van den Berg, M. S. van der Knaap, G. H. J. Boers, C. D. A. Stehouwer, J. A. Rauwerda, and J. Valk, “Hyperhomocysteinaemia; with reference to its neuroradiological aspects,” Neuroradiology, vol. 37, no. 5, pp. 403–411, 1995. View at: Publisher Site | Google Scholar
  74. K. Eto, T. Asada, K. Arima, T. Makifuchi, and H. Kimura, “Brain hydrogen sulfide is severely decreased in Alzheimer's disease,” Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1485–1488, 2002. View at: Publisher Site | Google Scholar
  75. U. Sen, P. Basu, O. A. Abe et al., “Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure,” American Journal of Physiology—Renal Physiology, vol. 297, no. 2, pp. F410–F419, 2009. View at: Publisher Site | Google Scholar
  76. S.-K. Yan, T. Chang, H. Wang, L. Wu, R. Wang, and Q. H. Meng, “Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 351, no. 2, pp. 485–491, 2006. View at: Publisher Site | Google Scholar
  77. H. Lee, E.-J. Lee, Y. S. Song, and E. Kim, “Long-term depression-inducing stimuli promote cleavage of the synaptic adhesion molecule NGL-3 through NMDA receptors, matrix metalloproteinases and presenilin/γ-secretase,” Philosophical Transactions of the Royal Society of London B: Biological Sciences, vol. 369, no. 1633, Article ID 20130158, 2014. View at: Publisher Site | Google Scholar
  78. P. K. Kamat, P. Kyles, A. Kalani, and N. Tyagi, “Hydrogen sulfide ameliorates homocysteine-induced Alzheimer’s disease-like pathology, blood–brain barrier disruption, and synaptic disorder,” Molecular Neurobiology, vol. 53, no. 4, pp. 2451–2467, 2016. View at: Publisher Site | Google Scholar
  79. X. Xu, C. Liu, Z. Li, and T. Zhang, “Effects of hydrogen sulfide on modulation of theta–gamma coupling in hippocampus in vascular dementia rats,” Brain Topography, vol. 28, no. 6, pp. 879–894, 2015. View at: Publisher Site | Google Scholar
  80. K. Qu, C. P. L. H. Chen, B. Halliwell, P. K. Moore, and P. T.-H. Wong, “Hydrogen sulfide is a mediator of cerebral ischemic damage,” Stroke, vol. 37, no. 3, pp. 889–893, 2006. View at: Publisher Site | Google Scholar
  81. I. Ishii, N. Akahoshi, H. Yamada, S. Nakano, T. Izumi, and M. Suematsu, “Cystathionine γ-lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury,” Journal of Biological Chemistry, vol. 285, no. 34, pp. 26358–26368, 2010. View at: Publisher Site | Google Scholar
  82. Z. Li, Y. Wang, Y. Xie, Z. Yang, and T. Zhang, “Protective effects of exogenous hydrogen sulfide on neurons of hippocampus in a rat model of brain ischemia,” Neurochemical Research, vol. 36, no. 10, pp. 1840–1849, 2011. View at: Publisher Site | Google Scholar
  83. X. Wen, D. Qi, Y. Sun et al., “H2S attenuates cognitive deficits through Akt1/JNK3 signaling pathway in ischemic stroke,” Behavioural Brain Research, vol. 269, pp. 6–14, 2014. View at: Publisher Site | Google Scholar
  84. Z.-L. Chen, W.-M. Yu, and S. Strickland, “Peripheral regeneration,” Annual Review of Neuroscience, vol. 30, no. 1, pp. 209–233, 2007. View at: Publisher Site | Google Scholar
  85. K. Bhatheja and J. Field, “Schwann cells: origins and role in axonal maintenance and regeneration,” The Journal of Biochemistry and Cell Biology, vol. 38, no. 12, pp. 1995–1999, 2006. View at: Publisher Site | Google Scholar
  86. W. W. Campbell, “Evaluation and management of peripheral nerve injury,” Clinical Neurophysiology, vol. 119, no. 9, pp. 1951–1965, 2008. View at: Publisher Site | Google Scholar
  87. D. Levy, P. Kubes, and D. W. Zochodne, “Delayed peripheral nerve degeneration, regeneration, and pain in mice lacking inducible nitric oxide synthase,” Journal of Neuropathology & Experimental Neurology, vol. 60, no. 5, pp. 411–421, 2001. View at: Publisher Site | Google Scholar
  88. S. Rangaraju, D. Hankins, I. Madorsky et al., “Molecular architecture of myelinated peripheral nerves is supported by calorie restriction with aging,” Aging Cell, vol. 8, no. 2, pp. 178–191, 2009. View at: Publisher Site | Google Scholar
  89. H. Rösch, R. Schweigreiter, T. Bonhoeffer, Y.-A. Barde, and M. Korte, “The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 20, pp. 7362–7367, 2005. View at: Publisher Site | Google Scholar
  90. G. Dechant and Y.-A. Barde, “The neurotrophin receptor p75NTR: novel functions and implications for diseases of the nervous system,” Nature Neuroscience, vol. 5, no. 11, pp. 1131–1136, 2002. View at: Publisher Site | Google Scholar
  91. J. Scheib and A. Höke, “Advances in peripheral nerve regeneration,” Nature Reviews Neurology, vol. 9, no. 12, pp. 668–676, 2013. View at: Publisher Site | Google Scholar
  92. X. Fontana, M. Hristova, C. Da Costa et al., “C-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling,” Journal of Cell Biology, vol. 198, no. 1, pp. 127–141, 2012. View at: Publisher Site | Google Scholar
  93. H. K. Lee, Y. K. Shin, J. Jung, S.-Y. Seo, S.-Y. Baek, and H. T. Park, “Proteasome inhibition suppresses schwann cell dedifferentiation in vitro and in vivo,” Glia, vol. 57, no. 16, pp. 1825–1834, 2009. View at: Publisher Site | Google Scholar
  94. J. Jung, W. Cai, S. Y. Jang et al., “Transient lysosomal activation is essential for p75 nerve growth factor receptor expression in myelinated Schwann cells during Wallerian degeneration,” Anatomy & Cell Biology, vol. 44, no. 1, pp. 41–49, 2011. View at: Publisher Site | Google Scholar
  95. G. Yang, W. Yang, L. Wu, and R. Wang, “H2S, endoplasmic reticulum stress, and apoptosis of insulin-secreting beta cells,” Journal of Biological Chemistry, vol. 282, no. 22, pp. 16567–16576, 2007. View at: Publisher Site | Google Scholar
  96. R. Wang, “Signaling pathways for the vascular effects of hydrogen sulfide,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 2, pp. 107–112, 2011. View at: Publisher Site | Google Scholar
  97. H. Kimura, N. Shibuya, and Y. Kimura, “Hydrogen sulfide is a signaling molecule and a cytoprotectant,” Antioxidants & Redox Signaling, vol. 17, no. 1, pp. 45–57, 2012. View at: Publisher Site | Google Scholar
  98. N. Krishnan, C. Fu, D. J. Pappin, and N. K. Tonks, “H2S-induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response,” Science Signaling, vol. 4, no. 203, article ra86, 2011. View at: Publisher Site | Google Scholar
  99. R. D. Di Villa Bianca, R. Sorrentino, P. Maffia et al., “Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 11, pp. 4513–4518, 2009. View at: Publisher Site | Google Scholar
  100. N. Barbera, A. Montana, F. Indorato, N. Arbouche, and G. Romano, “Domino effect: an unusual case of six fatal hydrogen sulfide poisonings in quick succession,” Forensic Science International, vol. 260, pp. e7–e10, 2016. View at: Publisher Site | Google Scholar
  101. K. R. Olson and N. L. Whitfield, “Hydrogen sulfide and oxygen sensing in the cardiovascular system,” Antioxidants & Redox Signaling, vol. 12, no. 10, pp. 1219–1234, 2010. View at: Publisher Site | Google Scholar
  102. T. Chang, A. Untereiner, J. Liu, and L. Wu, “Interaction of methylglyoxal and hydrogen sulfide in rat vascular smooth muscle cells,” Antioxidants and Redox Signaling, vol. 12, no. 9, pp. 1093–1100, 2010. View at: Publisher Site | Google Scholar
  103. H. Kimura, “Hydrogen sulfide: from brain to gut,” Antioxidants and Redox Signaling, vol. 12, no. 9, pp. 1111–1123, 2010. View at: Publisher Site | Google Scholar
  104. W.-L. Yin, J.-Q. He, B. Hu, Z.-S. Jiang, and X.-Q. Tang, “Hydrogen sulfide inhibits MPP+-induced apoptosis in PC12 cells,” Life Sciences, vol. 85, no. 7-8, pp. 269–275, 2009. View at: Publisher Site | Google Scholar
  105. L.-F. Hu, M. Lu, Z.-Y. Wu, P. T.-H. Wong, and J.-S. Bian, “Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function,” Molecular Pharmacology, vol. 75, no. 1, pp. 27–34, 2009. View at: Publisher Site | Google Scholar
  106. Y. Geng, E. Li, Q. Mu et al., “Hydrogen sulfide inhalation decreases early blood-brain barrier permeability and brain edema induced by cardiac arrest and resuscitation,” Journal of Perinatology, vol. 35, no. 3, pp. 494–500, 2015. View at: Publisher Site | Google Scholar
  107. K. Kida, E. Marutani, R. K. Nguyen, and F. Ichinose, “Inhaled hydrogen sulfide prevents neuropathic pain after peripheral nerve injury in mice,” Nitric Oxide—Biology and Chemistry, vol. 46, pp. 87–92, 2015. View at: Publisher Site | Google Scholar
  108. W.-L. Chen, Y.-Y. Niu, W.-Z. Jiang et al., “Neuroprotective effects of hydrogen sulfide and the underlying signaling pathways,” Reviews in the Neurosciences, vol. 26, no. 2, pp. 129–142, 2015. View at: Publisher Site | Google Scholar
  109. J. L. Wallace and R. Wang, “Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter,” Nature Reviews Drug Discovery, vol. 14, no. 5, pp. 329–345, 2015. View at: Publisher Site | Google Scholar
  110. S. Fiorucci, S. Orlandi, A. Mencarelli et al., “Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis,” British Journal of Pharmacology, vol. 150, no. 8, pp. 996–1002, 2007. View at: Publisher Site | Google Scholar
  111. J. L. Wallace, “Hydrogen sulfide-releasing anti-inflammatory drugs,” Trends in Pharmacological Sciences, vol. 28, no. 10, pp. 501–505, 2007. View at: Publisher Site | Google Scholar
  112. Y.-P. Yu, X.-L. Chi, and L.-J. Liu, “A hypothesis: hydrogen sulfide might be neuroprotective against subarachnoid hemorrhage induced brain injury,” The Scientific World Journal, vol. 2014, Article ID 432318, 9 pages, 2014. View at: Publisher Site | Google Scholar
  113. Y. Cui, X. Duan, H. Li et al., “Hydrogen sulfide ameliorates early brain injury following subarachnoid hemorrhage in rats,” Molecular Neurobiology, 2015. View at: Publisher Site | Google Scholar
  114. E. Cadenas and L. Packer, Hydrogen Sulfide in Redox Biology, Academic Press, Elsevier, 2015.
  115. E. Lim, O. Mbowe, A. S. Lee, and J. Davis, “Effect of environmental exposure to hydrogen sulfide on central nervous system and respiratory function: a systematic review of human studies,” International Journal of Occupational and Environmental Health, vol. 22, no. 1, pp. 80–90, 2016. View at: Publisher Site | Google Scholar
  116. M. Zhang, H. Shan, P. Chang et al., “Hydrogen sulfide offers neuroprotection on traumatic brain injury in parallel with reduced apoptosis and autophagy in mice,” PLoS ONE, vol. 9, no. 1, Article ID e87241, 2014. View at: Publisher Site | Google Scholar

Copyright © 2016 Sandesh Panthi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles